Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Kite Pharma downgrade details — to Hold at Stifel on valuation; tgt $74 (75.10)Stifel downgrades KITE to Hold from Buy and sets target price at $74 based on valuation in front of a launch that seems unlikely to be better than our models. Firm found Wednesday's data to be highly compelling with nearly a third of patients experiencing what looks like life-saving treatment. Nonetheless, co now faces a unique launch with treatment centers that have not all used these cells before and are likely to move slowly. In addition, firm still awaits a pricing announcement that is likely to trigger the heel-dragging that payors are becoming comfortable with. Finally, until more data for JCAR017 are released, the stock will continue to be plagued by doubts that <strong>Juno's</strong> (JUNO) cells may be meaningfully better. Despite the high chances for approval, firm doesn't see the conventional counter argument that Kite could be acquired. Firm sees only a handful of cos as sophisticated enough to take Kite over without destroying co (<strong>Amgen</strong> and <strong>Roche</strong>/Genentech) and both these cos are highly involved with competing, non-cellular, technologies.</td> </tr></table>"